pharmaphorum28m
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
pharmaphorum2h
FDA clears first drug for Niemann-Pick disease
Zevra Therapeutics' Miplyffa has become the first medicine to be approved by the FDA for the ultra-rare genetic disorder ...
pharmaphorum3h
FTC sues PBMs over 'perverse' rebate system
The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a ...
pharmaphorum2h
J&J tries to push talc bankruptcy over the line once again
Johnson & Johnson's long-running effort to put litigation claiming its talc products caused cancer has continued with a third attempt to place a subsidiary company into bankruptcy. Red River Talc LLC ...
pharmaphorum1d
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a date of 10th June to ...